黑色素瘤全身治疗降阶梯的现状与新兴机会:范围综述
本范围综述检索2013年1月至2023年6月MEDLINE、EMBASE和PubMed等来源,纳入301篇关于成人皮肤黑色素瘤全身治疗降阶梯的研究。主要降阶梯策略包括缩短疗程、减量、生物标志物指导、新辅助和/或反应适应等,但多数数据为回顾性,仅5项随机对照试验(2项为试验方案),患者报告结局报告率低。缩短抗PD-1治疗时长和新辅助策略前景较大,未来试验应优先纳入患者报告结局并明确生物标志物的临床效用。
要点
- 缩短抗PD-1治疗时长和新辅助策略是黑色素瘤降阶梯治疗的主要前景方向。
- 现有降阶梯证据多为回顾性研究,随机对照试验仅5项且其中2项为试验方案。
- 早期生物标志物研究占66%(198/301),但很少进入临床验证或效用试验。
核心结论
- 缩短抗PD-1治疗时长和新辅助策略在黑色素瘤降阶梯中前景较大。
- 未来试验应优先一致纳入患者报告结局并明确生物标志物的临床效用。
研究设计与样本
- 范围综述,检索MEDLINE、EMBASE和PubMed(2013年1月至2023年6月)及Google Scholar和回溯引文。
- 共筛选3721篇文章,纳入301篇:31篇非系统综述、198篇早期生物标志物研究、72篇降阶梯方法研究。
- 两名评价者使用Covidence进行筛选和数据提取,采用描述性统计并按PRISMA-ScR报告。
主要发现
- 降阶梯方法归纳为五类:缩短疗程、减量、生物标志物指导、新辅助和/或反应适应、及其他。
- 多数数据为回顾性;A类(降阶梯方法)仅纳入5项随机对照试验,其中2项为试验方案。
- 早期生物标志物研究占66%(n=198/301),很少进展至临床验证/效用试验。
- A类研究中患者报告结局仅占11%(n=5/45)。
临床怎么用
- 当前临床可关注缩短抗PD-1治疗时长和新辅助降阶梯策略,但需结合有限证据个体化决策。
- 开展降阶梯实践或试验时应系统收集患者报告结局,并推动生物标志物临床效用验证。
局限性
- 多数纳入研究为回顾性,随机对照证据少且部分为试验方案。
- 早期生物标志物研究占多数但很少进入临床验证,患者报告结局报告率低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is growing interest in optimising melanoma management to reduce over-treatment and improve patient safety and quality-of-life, yet clinical guidance on deintensification is minimal. This scoping review characterises the role of systemic therapies and biomarkers in current and emerging melanoma deintensification strategies. Study types, funding sources, and use of patient-reported outcomes (PRO) were also summarised. METHODS: MEDLINE, EMBASE and PubMed searches identified studies on deintensification in adult patients with cutaneous melanoma (January 2013 to June 2023). Additional texts were sourced via Google Scholar and backward citation searches. Three extraction tools were tailored to accommodate the breadth of articles included: A) deintensification approaches including biomarkers in late-phase development; B) non-systematic reviews; and C) early-phase biomarkers. Screening and data extraction were performed by two reviewers using Covidence. Data were analysed using descriptive statistics with results reported as per PRISMA-ScR guidelines. RESULTS: Of 3721 articles screened, 301 articles were included: 31 non-systematic reviews, 198 early-phase biomarker studies, and 72 studies on deintensification approaches. Five key approaches emerged: shortened duration of therapy, dose attenuation, biomarker-informed, neoadjuvant and/or response-adapted, and miscellaneous. Most data were retrospective; only five randomised controlled trials were included in Category A (two were trial protocols). Early-phase biomarker studies comprised 66 % (n = 198/301) of articles - few progressed to trials of clinical validation/utility. PRO were reported in 11 % (n = 5/45) of Category A studies. CONCLUSIONS: Shortened duration of anti-PD-1 therapy and neoadjuvant approaches hold substantial promise in deintensification. Future trials should prioritise consistent incorporation of PRO and focus on determining clinical utility of biomarkers.
引用
- Soon JA, Franchini F, Gourlay P, et al. Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review. Eur J Cancer. 2025. PMID: 41389770. doi:10.1016/j.ejca.2025.116132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。